Publications by authors named "A Trigoni"
Article Synopsis
- Psoriasis is a skin and nail disease linked to various health issues, including depression and metabolic conditions.
- A study involving 80 participants aimed to explore the relationship between inflammation markers (CRP and ESR) and depression in psoriasis patients.
- Results showed that both CRP and ESR levels were elevated in psoriasis patients, especially those with depression, suggesting these markers could help identify depression in psoriasis for better treatment approaches.
Eccrine poroma (EP) is a relatively rare benign adnexal neoplasm that usually affects elderly patients. Its pathogenesis is still under investigation, but recent gene studies have revealed gene fusions as key incidences resulting in oncogenetic pathways. It often presents as a solitary, firm papule, mostly asymptomatic, located on the soles or palms.
View Article and Find Full Text PDFArticle Synopsis
- * Results showed that patients carrying a common genetic variant (GGG haplotype) had a significantly better response to ADA after 12 weeks compared to those with less common SNPs, with response rates of 71.8% vs. 50.0%.
- * The findings suggest that those with minor SNP haplotypes had a lower improvement in certain measures of disease severity, indicating that genetic makeup could influence treatment outcomes and should be considered in clinical decisions.
Introduction: Nail toxicity represents one of the most common cutaneous adverse effects of both classic chemotherapeutic agents and new oncologic drugs, including targeted treatments and immunotherapy.
Objectives: We aimed to provide a comprehensive literature review of nail toxicities derived from conventional chemotherapeutic agents, targeted therapies (EGFR inhibitors, multikinase inhibitors, BRAF and MEK inhibitors) and immune checkpoint inhibitors (ICIs), including clinical presentation, implicated drugs and approaches for prevention and management.
Methods: Retrieved literature from PubMed registry database was reviewed to include all articles published up to May 2021 relevant to the clinical presentation, diagnosis, incidence, prevention, and treatment of oncologic treatment-induced nail toxicity.
Article Synopsis
- A new parameter called IHS4-55, which indicates a 55% reduction in the severity of Hidradenitis Suppurativa (HS), was validated using data from patients treated with adalimumab and placebo.
- The research aimed to externally validate the IHS4-55 in patients treated with antibiotics, assessing its correlation with the reduction of inflammatory lesions and quality of life metrics.
- Results from a study of 283 patients showed that those achieving IHS4-55 experienced significant reductions in inflammatory nodules and had a greater likelihood of improving quality of life scores, supporting its use as a key outcome measure in clinical trials.